Brady, Walden Statement on Administration’s Medicare Drug Pricing Proposals

Brady, Walden Statement on Administration's Medicare Drug Pricing Proposals

October 25, 2018

Rob Damschen, Jesse Solis (202) 226-4774

Washington, D.C. - Today, House Committee on Ways and Means Chairman Kevin Brady (R-TX) and House Committee on Energy and Commerce Chairman Greg Walden (R-OR) issued the following statement following President Donald Trump's speech on drug pricing: "There's no question that Americans pay too much for their health care, including the cost of prescription drugs. Progress has been made to encourage more domestic competition and speeding generic drugs to market, but more needs to be done. From his first days in office, President Trump made it clear that we must take decisive action to reduce the burdens felt by families and seniors who rely on these important medications. We commend the President for remaining steadfast in his commitment and appreciate Secretary of Health and Human Services Azar's efforts to encourage lower drug costs for patients. "We will continue working with President Trump and his Administration to make good on his promise to the American people and will continue the Ways and Means Committee's and Energy and Commerce Committee's efforts to create an affordable and competitive marketplace for prescription drugs while maintaining our nation's leadership role in medical innovation and ensuring patient access to new, lifesaving therapies." ###